相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer
Neeraj Agarwal et al.
CLINICAL CANCER RESEARCH (2020)
Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization
Minh-Phuong Huynh-Le et al.
CLINICAL GENITOURINARY CANCER (2020)
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Matthew Smith et al.
LANCET ONCOLOGY (2019)
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
Michael J. Morris et al.
EUROPEAN JOURNAL OF CANCER (2019)
Factors affecting 223Ra therapy: clinical experience after 532 cycles from a single institution
Elba C. Etchebehere et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Fred Saad et al.
LANCET ONCOLOGY (2016)
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor et al.
LANCET ONCOLOGY (2014)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
分享论文
